|
1
|
Zhang J, Xie X and Ye D: Adhesion
molecules and tumor immune escape. Shi Yong Zhong Liu Xue Zha Zhi.
19:449–452. 2004.(In Chinese).
|
|
2
|
Ogiso Y, Tomida A, Lei S, et al:
Proteasome inhibition circumvents solid tumor resistance to
topoisomerase II-directed drugs. Cancer Res. 60:2429–2434.
2000.PubMed/NCBI
|
|
3
|
Fink T, Ebbesen P, Koppelhus U and Zachar
V: Natural Killer cell-mediated basal and interferon-enhanced
cytotoxicity against liver cancer cells is significantly impaired
under in vivo oxygen conditions. Scand J Immunol. 58:607–612. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ivan M: HIF-1α targeted for VHL-mediated
destruction by praline hydroxylation: implications for
O2 sensing. Science. 292:464–468. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Semenza G: Signal transduction to
hypoxia-inducible factor 1. Biochem Pharmacol. 64:993–998. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ivan M: HIF-1α targeted for VHL-mediated
destruction by praline hydroxylation: implications for
O2 sensing. Science. 292:464–468. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Groh V, Rhinehart R, Secrist H, et al:
Broad tumor-associated expression and recognition by tumor-derived
gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA.
96:6879–6884. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li K, Mandai M, Hamanishi J, et al:
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in
ovarian cancer: high expression of ULBP2 is an indicator of poor
prognosis. Cancer Immunol Immunother. 58:641–652. 2009. View Article : Google Scholar
|
|
9
|
Diefenbach A, Jensen ER, Jamieson AM and
Raulet DH: Rael and H60 ligands of the NKG2D receptor stimulate
tumour immunity. Nature. 413:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Groh V, Steinle A, Bauer S and Spies T:
Recognition of stress-induced MHC molecu1es by intestina1
epithelial gammadelta T cel1s. Science. 279:1737–1740. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Conejo-Garcia JR, Benencia F, Courreges
MC, et al: A tumor-associated NKG2D immunoreceptor ligand, induces
activation and expansion of effector immune cells. Cancer Biol
Ther. 2:446–451. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vivier E, Tomasello E and Paul P:
Lymphocyte activation via NKG2D: towards a new paradigm in immune
recognition. Curr Opin Immunot. 14:306–311. 2002. View Article : Google Scholar
|
|
13
|
Holdenrieder S, Stieber P, Peterfi A, et
al: Soluble MICA in malignant diseases. Int Cancer. 118:684–687.
2006. View Article : Google Scholar
|
|
14
|
Li K, Mandai M, Hamanishi J, Matsumura N,
et al: Clinical significance of the NKG2D ligands, MICA/B and ULBP2
in ovarian cancer: high expression of ULBP2 is an indicator of poor
prognosis. Cancer Immunol Immunother. 58:641–652. 2009. View Article : Google Scholar
|
|
15
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
16
|
Duan X, Deng L, Chen X, et al: Clinical
significance of the immunostimulatory MHC class I chain-related
molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med
Oncol. 28:466–467. 2011. View Article : Google Scholar
|
|
17
|
Peng TS, Wu JS, Wu HQ, et al: The
expression of matrix metalloproteinase-2,9 and their inhibitors in
osteosarcoma. Journal of Sun Yatsen University (Medical Sciences).
2:132–135. 2003.(In Chinese).
|
|
18
|
Salih HR, Rammensee HG and Steinle A:
Down-regulation of MICA on human tumors by proteolytic shedding. J
Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siemens DR, Hu N, Sheikhi AK, et al:
Hypoxia increases tumor cell shedding of MHC class I chain-related
molecule: role of nitric oxide. Cancer Res. 68:4746–4753. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Doubrovina ES, Doubrovin MM, Vider E, et
al: Evasion from NK cell immunity by MHC class I chain-re1ated
molecules expressing colon adenocarcinoma. J Immunol.
171:6891–6899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Groh V, Wu J, Yee C and Spies T:
Tumour-derived soluble MIC ligands impair expression of NKG2D and
T-cell activation. Nature. 419:679–680. 2002. View Article : Google Scholar
|
|
22
|
Whorton AR, Simonds DB and Piantadosi CA:
Regulation of nitric oxide synthesis by oxygen in vascular
endothelial cells. Am J Physiol. 272:L1161–L1166. 1997.PubMed/NCBI
|
|
23
|
McCormick CC, Li WP and Calero M: Oxygen
tension limits nitric oxide synthesis by activated macrophages.
Biochem J. 350:709–716. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nathan C and Xie QW: Regulation of
biosynthesis of nitric oxide. J Biol Chem. 269:13725–13728.
1994.PubMed/NCBI
|
|
25
|
Louis CA, Reichner JS, Henry WL Jr, et al:
Distinct arginase isoforms expressed in primary and transformed
macrophages: regulation by oxygen tension. Am J Physiol.
274:R775–R782. 1998.PubMed/NCBI
|
|
26
|
Frederiksen LJ, Sullivan R, Maxwell LR, et
al: Chemosensitization of cancer in vitro and in vivo by nitric
oxide signaling. Clin Cancer Res. 13:2199–2206. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Postovit LM, Adams MA, Lash GE, Heaton JP
and Graham CH: Oxygen-mediated regulation of tumour cell
invasiveness: involvement of a nitric oxide signalling pathway.
Biol Chem. 277:35730–35737. 2002. View Article : Google Scholar
|
|
28
|
Postovit LM, Adams MA, Lash GE, Heaton JP
and Graham CH: Nitric oxide-mediated regulation of hypoxia-induced
B16F10 melanoma metastasis. Int J Cancer. 108:47–53. 2004.
View Article : Google Scholar
|
|
29
|
Matthews NE, Adams MA, Maxwell LR, Gofton
TE and Graham CH: Nitric oxide-mediated regulation of
chemosensitivity in cancer cells. Natl Cancer Inst. 93:1879–1885.
2001. View Article : Google Scholar
|
